Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 16258083

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2005 Nov 1
First author
Tan-Chiu E

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2005 Nov 1;23(31):7775-6. doi: 10.1200/JCO.2005.04.1558.
    note
    Source null
    related pmid
    16258081
    relationship
    Comment in

Authors and identifiers

  1. name
    Tan-Chiu E
    type
    Author
  2. name
    Yothers G
    type
    Author
  3. name
    Romond E
    type
    Author
  4. name
    Geyer CE Jr
    type
    Author
  5. name
    Ewer M
    type
    Author
  6. name
    Keefe D
    type
    Author
  7. name
    Shannon RP
    type
    Author
  8. name
    Swain SM
    type
    Author
  9. name
    Brown A
    type
    Author
  10. name
    Fehrenbacher L
    type
    Author
  11. name
    Vogel VG
    type
    Author
  12. name
    Seay TE
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Tan-Chiu E
    type
    Author
  2. name
    Yothers G
    type
    Author
  3. name
    Romond E
    type
    Author
  4. name
    Geyer CE Jr
    type
    Author
  5. name
    Ewer M
    type
    Author
  6. name
    Keefe D
    type
    Author
  7. name
    Shannon RP
    type
    Author
  8. name
    Swain SM
    type
    Author
  9. name
    Brown A
    type
    Author
  10. name
    Fehrenbacher L
    type
    Author
  11. name
    Vogel VG
    type
    Author
  12. name
    Seay TE
    type
    Author
bibliography ids
  1. nci-bib-3edf5796d8a307d8ccaa6fdd
book metadata
content sha256
ae0466cd6eb91c710c4205942270a767386d7e6a5e1f3c4c2f535b8ea577133a
document type
citation
dois
  1. 10.1200/JCO.2005.02.4091
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:16258083
immutable id
pubmed:16258083@ae0466cd6eb91c710c4205942270a767386d7e6a5e1f3c4c2f535b8ea577133a
journal
abbreviation
J Clin Oncol
issn electronic
Source null
issn print
0732-183X
issue
31
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
7811-9
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2005 Nov 1;23(31):7775-6. doi: 10.1200/JCO.2005.04.1558.
    note
    Source null
    related pmid
    16258081
    relationship
    Comment in
outcomes validated
false
pmid
16258083
provenance
batch id
a181c30258a88d182e78
provider
NCBI PubMed ESummary
record sha256
338ddb5be810182dc76a794b16f1e567a21808c6ff059f8d3447f42638de911b
response sha256
558e0dce453ae424567844b062522ebd1d27363c3312c81dbf6f32a8ff08da24
retrieved at
2026-09-09T23:46:03.896343+00:00
publication date
display
2005 Nov 1
precision
day
year
2005
publication types
  1. Comparative Study
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, N.I.H., Extramural
  5. Research Support, Non-U.S. Gov't
  6. Research Support, U.S. Gov't, P.H.S.
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/16258083/
title
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Preserved source evidence · Not medical advice